Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 1,630

Document Document Title
WO/2007/086898A2
Disclosed are compositions and methods relating to the anthrax spore glycoproteins of Bacillus anthracis. Disclosed are the methods of using these compositions for vaccination against anthrax infection. Disclosed are BclA and BclB, compo...  
WO/2007/051923A3
The invention relates to novel biodegradable materials based on modified polyomino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant...  
WO/2007/064208A1
A protein hydrolysate having a degree of hydrolysis between 1 and 40% and containing between 1 and 70 wt.% of peptides having a molecular weight of less than 500 Da and less than 55 wt.% of peptides or proteins having a molecular weight ...  
WO/2006/039707A3
A series of mutants of Anthrax lethal factor (LF) are disclosed which define a conformational epitope or region of the molecule that interacts with the LF target, the MEK enzyme. Such mutants or variants, and nucleic acids encoding them ...  
WO/2007/033233A3
This document provides methods and materials related to activating GPCRs. For example, methods and materials for activating GPCRs present on cells (e.g., human cell) as well as methods and materials for identifying GPCR agonists are prov...  
WO/2007/059597A2  
WO/2003/089601A3
The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, ...  
WO/2000/009653A3
A novel procathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of cathepsin K and methods of designing inhibitors of cathepsin K using structural and physical data based on the crystallog...  
WO/2003/077872A3
The present invention is directed to novel methods for inhibiting angiogenesis and treating tumors and cancer by targeting tropomyosin (Tpm) expressed on the surface of endothelial cells and/or tumor cells, to Tpm polypeptides and peptid...  
WO/2006/039326A3
The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has p...  
WO/2007/051923A2
The invention relates to novel biodegradable materials based on modified polyomino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant...  
WO/2007/045192A1
Disaccharide synthon I (benzyl-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-2-ac etamido-3-0-[1-(R)-carboxyethyl-2-deoxy-α-D-glucopyranoside ) and its use for synthesis of 2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-N-acetylmura ...  
WO/2006/083706A3
The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The i...  
WO/2007/043615A1
Disclosed is a method for ligation of proteins or constituent components thereof (e.g., amino acids, peptides) through an amide bond by using a peptide ester as a raw material. Also disclosed is a reagent which can be used suitably in th...  
WO2006017913A9
The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conse...  
WO/2004/058189A3
The present invention provides a chemokine peptide antagonist comprising the N-terminal domain of a CXCR1 receptor. The native amino acid(s) of such N-terminal domain is replaced by one or more histidine residues, thereby forming Zn(II) ...  
WO/2006/056443A3
Use of an activated solid phase and a peptide-conjugated anchoring part for solid phase peptide synthesis, wherein the anchoring part is coordinatively and reversibly attached to the activated solid phase.  
WO/2007/033424A1
The present invention is concerned with compositions capable of transfecting or otherwise delivering useful substances into cells and, more specifically, it is concerned with proteins and peptides capable of translocation across cell mem...  
WO/2007/034809A1
It is intended to provide a host cell which can be proliferated in a serum-free medium, synthesize and secret a desired protein in a large amount and produce a glycoprotein having a sugar chain structure. Namely, an established cell line...  
WO/2007/030889A1
The present invention relates to a marker for the development of pre-eclampsia. In particular the invention provides a marker for the development of pre-eclampsia, which marker consists of a polypeptide of approximately 26.6 Kd as determ...  
WO/2006/086562A3
Various azetidinone derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.  
WO/2007/032634A1
The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natu...  
WO/2006/066214A3
The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of ...  
WO/2007/030890A1
The present invention relates to amniotic fluid specific polypeptide and a method for detecting rupture of the amniotic membranes. In particular the invention provides a marker for prolonged rupture of the membranes (PROM), which marker ...  
WO/2005/007831A3
The present invention provides compositions of protein mimetics and methods of using same against HIV-1, SARS-coV and the like. In one aspect, the present invention relates to a protein mimetic for preventing HIV-1 entry to host cells of...  
WO/2006/103666A3
The present invention relates to a PIKK-phosphorylated BID polypeptide which can be used to induce cell cycle arrest. Specifically, the present invention provides isolated polypeptides comprising a BID amino acid sequence which can be us...  
WO/2007/021016A1
A method for photoregulating the formation of a complex between a protein of interest and a peptide capable of recognizing the protein, wherein a structural change in the peptide that is used for the recognition of the protein is photore...  
WO/2007/021253A1
The inventors have discovered that an ATPase-deficient dominant­negative mutant NS3 protein of hepatitis C virus inhibits activity of the wild-type NS3 protein and inhibits replication of hepatitis C virus (HCV). The solved crystal stru...  
WO/2005/122379A3
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  
WO/2006/031607A3
The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator ...  
WO/2006/096829A3
The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancre...  
WO/2006/031814A3
A method for electrochemical removal of acid-labile protecting groups on an electrode microarray using an organic solution is disclosed. The solution comprises a hydrazine derivative and a salt in an organic solvent. The hydrazine deriva...  
WO/2006/019982A3
The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease.  
WO/2006/138721A1
Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit...  
WO2004041067A3
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that ind...  
WO2005062967A3
The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate mola...  
WO/2006/135371A1
A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent ahs been modified by attachment of a cell membrane-impermeabilizing group so that, if the active agent so modified is clea...  
WO/2006/133196A1
The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptide...  
WO/2006/128027A1
A method is disclosed for inhibiting angiogenic activity by interacting anginex with the peptide galectin-1. Also disclosed is a method for constructing an artificial gene encoding the biologically exogenous peptide anginex and producing...  
WO2005009379A3
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative...  
WO2005086967A3
The antigen recognized by RM1 antibody is used for therapy, diagnosis and imaging.  
WO/2006/114528A1
The invention relates to the use of monomers of active a-amino acids for the preparation of hydrophobic polypeptides in the form of precipitates, whereby the polypeptides result from the polymerisation of the aforementioned monomers of a...  
WO2005049638A3
The present invention relates to the method(s) of synthesis of and the therapeutic and cosmetic applications of biologically active peptides for improving the appearance of skin, for hastening wound healing and for treating and/or preven...  
WO/2006/111060A1
The present invention provides a method for isolating and purifying immuno-modulating polypeptide from cow placenta, which is characterized by using the steps of anion-exchange chromatography, gel exclusion chromatography and reverse-pha...  
WO2005086611A3
The present invention discloses methods of determining highly precise interactions between a membrane protein receptor and various compounds. The methods of the present invention utilize a receptophore model system and nonsense codon sup...  
WO2006024026A3
Inhibitors of the mevalonate pathway are shown to affect the phosphorylation and activation of oncogenic signaling molecules, demonstrating a mechanism for the anti-proliferative activity of such agents. Methods are provided for predicti...  
WO2002050303A3
[0083] The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and dis...  
WO/2006/098326A1
Disclosed is a complex for a biocompatible material which has no risk of causing infection with a pathogen or any adverse side effect (e.g., rejection). A complex for a biocompatible material, comprising a polypeptide comprising peptide ...  
WO2003089588A3
Novel PYRIN-2, PYR1N-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN1111 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10,...  
WO2006055623A3
Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided...  

Matches 351 - 400 out of 1,630